



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of:  
Dixit et al.

Docket No.: PF335D2

Application No.: 09/961,201

Filed: September 24, 2001 Art Unit: 1644

For: Interleukin-1 Beta Converting Enzyme Like  
Apoptosis Protease 6 Examiner: P. N. Huynh

**INFORMATION DISCLOSURE STATEMENT (IDS)**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to references AA-AQ listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed more than three months after the U.S. filing date, and after the mailing date of the first Office Action on the merits, whichever occurs first, but before the mailing date of a Final Office Action or Notice of Allowance (37 CFR 1.97(c)).

The PTO/SB/08 provided herewith lists references AA-AQ. Copies of references AA-AJ were submitted by Applicants in connection with U.S. Patent Application Serial No. 08/852,936, filed May 8, 1997 (now U.S. Patent No. 6,010,878). References AK-AL were cited by the Examiner in connection with U. S. Patent Application Serial No. 09/300,328, filed April 27, 1999 (now U.S. Patent No. 6,294,169). The instant application claims priority under 35 U.S.C. § 120 to each of the above-listed Patent Applications. Furthermore, pursuant to 37 C.F.R. § 1.98(d), the Examiner is directed to the files of the above-listed Patent Applications for

02/24/2004 MAHMED1 00000082 083425 09961201

01 FC:1806 180.00 DA

copies of references AA-AL. References AM-AQ were cited in an International Search Report mailed September 17, 1996, in connection with International Patent Application No. WO 97/46663, published on December 11, 1997. Copies of references AM-AQ are provided herewith.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

Please charge our Deposit Account No. 08-3425 in the amount of \$180.00 covering the fee set forth in 37 CFR 1.17(p). The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 08-3425, under Order No. PF335D2.

Dated: February 19, 2004

Respectfully submitted,

By L. J. Hymel

Lin J. Hymel

Registration No.: 45,414  
HUMAN GENOME SCIENCES, INC.  
14200 Shady Grove Road  
Rockville, Maryland 20850  
(301) 251-6015



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete if Known	
				Application Number	09/961,201-Conf. #6537
				Filing Date	September 24, 2001
				First Named Inventor	Vishva M. Dixit
				Art Unit	1644
				Examiner Name	P. N. Huynh
Sheet	1	of	2	Attorney Docket Number	PF335D2

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
AA	WO-93/00353		01-07-1993			

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
AB	Duan et al., "ICE-LAP3, a Novel Mammalian Homologue of the <i>Caenorhabditis elegans</i> Cell Death Protein Ced-3 Is Activated during Fas- and Tumor Necrosis Factor-induced Apoptosis," <i>The Journal of Biological Chemistry</i> , Vol. 271 (3), pp. 1621-1625 (1996).		
AC	Fernandes-Alnemri et al., "Mch3, a Novel Human Apoptotic Cysteine Protease Highly Related to CPP32," <i>Cancer Research</i> , Vol. 55, pp. 6045-6052 (1995).		
AD	GenBank Accession No. H39637, 8/4/95, Hillier, L. et al., Homo Sapiens cDNA Clone 1819835.		
AE	GenBank Accession No. T97582, 4/16/95, Hillier, L. et al., Homo Sapiens cDNA Clone 1216935.		
AF	Duan et al., "ICE-LAP6, a Novel Member of the ICE/CED-3 Gene Family, Is Activated by the Cytotoxic T Cell Protease Granzyme B," <i>The Journal of Biological Chemistry</i> , Vol. 271 (28), pp. 16720-16724 (1996).		
AG	Srinivasula et al., "The Ced-3/Interleukin 1-beta Converting Enzyme-like Homolog Mch6 and the Lamin-cleaving Enzyme Mch2-alpha Are Substrates for the Apoptotic Mediator CPP32," <i>The Journal of Biological chemistry</i> , Vol 271 (43), pp. 27099-27106 (1996).		
AH	Orkin et al., "Report and recommendations of the panel to assess the NIH investment in research on gene therapy," issued by the U.S. Nation Institutes of Health, 12/95.		
AI	Ngo et al., "Computational complexity, protein structure prediction, and the Levinthal paradox," <i>The Protein Folding Problem and Tertiary Structure Prediction</i> , Merx et al., Birkhauser Boston: Boston MA, pp. 433 and 492-495 (1994).		
AJ	Fernandes-Alnemri et al., "CPP32, a novel human apoptotic protein with homology to <i>Caenorhabditis elegans</i> cell death protein ced-3 and mammalian interleukin-1 beta converting enzyme," <i>Journal of Biological Chemistry</i> , Vol. 269 (49), pp. 30761-30764 (1994).		
AK	Cryns et al., "The cutting edge: caspases in apoptosis and disease," pages 177-210, When Cells Die, eds. Lockshin et al. New York: Willey-Liss, Inc. (1998).		
AL	PA Henkart, "ICE family proteases: mediators of all apoptotic cell death?," <i>Immunity</i> Vol. 4, pages 195-201, (1996).		

Examiner Signature	Date Considered
--------------------	-----------------



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/B/PTO				<i>Complete if Known</i>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				Application Number	09/961,201-Conf. #6537
Sheet	2	of	2	Filing Date	September 24, 2001
				First Named Inventor	Vishva M. Dixit
				Art Unit	1644
				Examiner Name	P. N. Huynh
				Attorney Docket Number	PF335D2

AM	Alnemri et al., "Cloning and Expression of four novel isoforms of human interleukin-1beta converting enzyme with different apoptotic activities," Journal of Biological Chemistry, 03 March 1995, Vol 270, No. 9, pages 4312-4317.	
AN	Tewari et al., "Yama/CPP32beta, a mammalian homolog of ced-3 is a crmA-inhibitable protease that cleaves the death substrate poly (ADP-ribose) polymerase," Cell, 02 June 1995, Vol. 81, No. 5, pages 801-809.	
AO	Wang et al., "Ich-1, an ICE/ced-3 related gene, encodes both positive and negative regulators of programmed cell death," Cell 09 September 1994, vol. 78, pages 739-750.	
AP	Thornberry et al., "Interleukin-1beta-converting enzyme and related proteases as potential targets in inflammation and apoptosis," Perspectives in Drug Discovery and Design, July 1995, Vol. 2, No. 3, pages 389-399.	
AQ	Kamens et al, "Identification and characterization of ICH-2, a novel member of the interleukin-1beta-converting family of cysteine proteases," Journal of Biological Chemistry, 23 June 1995, Vol. 270, No. 25, pages 15250-15256.	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	Date Considered
--------------------	-----------------